1 0 7 7 l e t t e r s Members of the NADPH oxidase (NOX) family of enzymes, which catalyze the reduction of O 2 to reactive oxygen species, have increased in number during eukaryotic evolution 1,2 . Seven isoforms of the NOX gene family have been identified in mammals; however, specific roles of NOX enzymes in mammalian physiology and pathophysiology have not been fully elucidated 3,4 . The best established physiological role of NOX enzymes is in host defense against pathogen invasion in diverse species, including plants 5,6 . The prototypical member of this family, NOX-2 (gp91 phox ), is expressed in phagocytic cells and mediates microbicidal activities 7,8 . Here we report a role for the NOX4 isoform in tissue repair functions of myofibroblasts and fibrogenesis. Transforming growth factor-1 (TGF-1) induces NOX-4 expression in lung mesenchymal cells via SMAD-3, a receptor-regulated protein that modulates gene transcription. NOX-4-dependent generation of hydrogen peroxide (H 2 O 2 ) is required for TGF-1-induced myofibroblast differentiation, extracellular matrix (ECM) production and contractility. NOX-4 is upregulated in lungs of mice subjected to noninfectious injury and in cases of human idiopathic pulmonary fibrosis (IPF). Genetic or pharmacologic targeting of NOX-4 abrogates fibrogenesis in two murine models of lung injury. These studies support a function for NOX4 in tissue fibrogenesis and provide proof of concept for therapeutic targeting of NOX-4 in recalcitrant fibrotic disorders.
Tissue repair in mammals involves the integrated actions of growth factors and matrix molecules that orchestrate cell-to-cell interactions [9] [10] [11] . Fibrosis of diverse tissues occurs when this process is dysregulated by impaired reepithelialization in association with myofibroblast activation 9, 11 . Myofibroblast differentiation and activation are dependent on TGF-β1, matrix signaling and biomechanical tension [12] [13] [14] . We have previously reported that myofibroblast differentiation by TGF-β1 is associated with the activation of a flavoenzyme that generates extracellular H 2 O 2 (refs. 15-17) . NOX-4 has been implicated in the differentiation of cardiac fibroblasts to myofibroblasts 18 . However, the physiological and pathophysiological roles for NOX-4 in tissue repair and fibrogenesis are not well defined.
We identified NOX4 as one of the most highly induced genes by whole-genome Affymetrix analysis in human fetal lung mesenchymal cells (hFLMCs) stimulated with TGF-β1; other members of the NOX gene family were not affected at the messenger RNA level (Fig. 1a) . We confirmed the upregulation of NOX4 mRNA by TGF-β1 by RT-PCR ( Supplementary Fig. 1a) , and NOX-4 protein expression was induced in a time-dependent manner ( Fig. 1b and Supplementary Fig. 1b) . To define the specific role of NOX4, we used an RNA interference (RNAi) approach using small interfering RNA (siRNA) targeting NOX4 (NOX4 siRNA). Two of four siRNA duplexes, duplex 3 and duplex 4, efficiently blocked NOX-4 induction by TGF-β1 ( Supplementary Fig. 1c ). We used the NOX4 siRNA duplex 4 in subsequent in vitro studies designed to examine the role for NOX-4 in myofibroblast differentiation and activation. RNAi-mediated knockdown of NOX-4 significantly inhibited TGF-β1-induced H 2 O 2 production in hFLMCs ( Fig. 1c) , implicating NOX-4 as the primary enzymatic source of extracellular H 2 O 2 generation by TGF-β1-differentiated myofibroblasts.
TGF-β1 signals via two heterodimeric transmembrane receptors, the type II and type I (activin receptor-like kinase-5, ALK5) receptors. To define upstream mechanisms of TGF-β1-induced NOX-4 induction and H 2 O 2 generation in myofibroblasts, we tested the effect of pharmacologic inhibitors of ALK5 and canonical mitogenassociated protein kinase (MAPK) pathways. Of these, only ALK5 inhibition attenuated the induction of H 2 O 2 production by hFLMCs ( Fig. 1d) . The ALK5 receptor is known to activate SMAD-2 and SMAD-3; however, profibrotic effects of TGF-β1 signaling have been largely attributed to SMAD-3 signaling 19 . We used an RNAi strategy to determine whether SMAD-3 is required for NOX-4 induction and H 2 O 2 generation in hFLMCs; SMAD3 siRNA knockdown inhibited TGF-β1-mediated NOX-4 inducibility ( Fig. 1e ) and H 2 O 2 production ( Fig. 1f) . Similarly, we observed a requirement for SMAD-3 signaling in TGF-β1-induced NOX-4 expression in primary mesenchymal cells isolated from lungs of human subjects with IPF ( Supplementary  Fig. 1d ), a chronic fibrosing and ultimately fatal lung disease. These data support a role for TGF-β1 signaling via ALK5 and SMAD-3 in the induction and activation of NOX-4 in myofibroblasts.
Myofibroblasts contribute to the tissue repair by secreting ECM proteins and remodeling and contracting the ECM 9, 11 . We used a 1 0 7 8 volume 15 | number 9 | SePTember 2009 nature medicine l e t t e r s three-dimensional collagen matrix cell culture system to determine whether fibronectin synthesis and contractile functions of myofibroblasts are regulated by NOX-4 activation and extracellular H 2 O 2 generation. The upregulation of α-smooth muscle actin (α-SMA), a cytoskeletal component of contractile actin stress fibers, and fibronectin synthesis induced by TGF-β1 were inhibited by addition of catalase ( Fig. 1g) , an enzyme that reduces H 2 O 2 to H 2 O, indicating a role for H 2 O 2 in mediating these effects. Similarly to the effects of catalase, endogenous suppression of NOX-4 by siRNA knockdown inhibited TGF-β1-induced expression of α-SMA, fibronectin and procollagen I ( Fig. 1h ). Next, we studied whether NOX-4-dependent H 2 O 2 production by myofibroblasts is required for their capacity to contract three-dimensional collagen gels. Both exogenous introduction of catalase and RNAi-mediated knockdown of NOX-4 inhibited TGF-β1-induced collagen gel contractility ( Fig. 1i,j) . Together, these studies indicate a crucial role for NOX-4-dependent H 2 O 2 in conferring synthetic and contractile properties to myofibroblasts that differentiate under the influence of TGF-β1.
To investigate a potential role for NOX-4 in a human fibrotic disease, we examined lung tissue sections from individuals with IPF. NOX-4 is highly expressed in myofibroblastic foci of the remodeled IPF lung, as determined by immunohistochemical staining ( Fig. 2a) . Additionally, we studied lung mesenchymal cells isolated from explants of IPF lung tissue (IPF-MCs) ex vivo. Similarly to our findings in hFLMCs, we found NOX-4 to be induced and necessary for TGF-β1-stimulated H 2 O 2 production ( Fig. 2b) ; NOX-4 was also required for the induction of α-SMA and fibronectin mRNA ( Fig. 2c-e ) and protein expression ( Fig. 2f ) by TGF-β1 in IPF-MCs. Differentiated myofibroblasts are known to secrete higher amounts of extracellular collagen. We evaluated the effect of NOX-4 on collagen secretion by IPF-MCs. Both constitutive and TGF-β1-induced secretion of soluble collagen by IPF-MCs were inhibited by siRNAmediated knockdown of NOX-4 ( Fig. 2g ). Next, we examined the role of NOX-4 in IPF-MC proliferation in response to serum; siRNAmediated knockdown of NOX-4 inhibited serum-stimulated proliferation of IPF-MCs ( Fig. 2h,i) . These data support a key role for NOX-4 in myofibroblast differentiation and proliferation of human IPF-MCs.
To define the in vivo role of NOX-4 in the reparative response to injury of the mammalian lung, we used a murine model of acute lung injury. In this model, direct airway instillation of the chemotherapeutic drug bleomycin causes epithelial injury with subsequent mesenchymal cell activation and fibrosis. Several key features of fibrotic reactions in mammalian tissues, including TGF-β1 upregulation and activation and myofibroblast differentiation and activation 20 . We first determined whether NOX-4 expression is induced during the fibrogenic phase of bleomycin-induced lung injury. NOX-4 expression was induced in a time-dependent manner, increasing from day 7 up to day 28 ( Fig. 3a) , supporting a temporal relationship between NOX-4 expression, myofibroblast activation and fibrosis after lung injury.
In contrast, expression of the NOX-2 isoform, which is predominantly expressed in phagocytic cells, was increased on day 7 and returned to baseline levels at later time points, when inflammatory responses had subsided (Fig. 3a) .
Next, we examined the effects of targeted suppression of NOX-4 induction with in vivo RNAi approach in two animal models of lung injury and fibrosis. We first confirmed that the mouse siRNA homologous to the human NOX4 siRNA duplex 4 ( Supplementary Table 1 ) efficiently knocked down NOX-4 expression in cultured primary murine mesenchymal cells (Supplementary Fig. 2a ). In the first mouse model, we instilled Nox4 siRNA or nontargeting control siRNA directly down the trachea of mice at the time of bleomycin injury (day 0), and we analyzed tissues at day 14 or 21. Nox4 siRNA was effective in inhibiting NOX-4 induction in injured lung tissue at 21 d, as determined by western immunoblotting (Fig. 3b) , and at day 14, as determined by immunohistochemical analysis (Fig. 3c) . Immunohistochemical analysis confirmed NOX-4 expression localized to fibrotic foci surrounding remodeled alveolar structures on day 14 after lung injury (Fig. 3c) . NOX-4 knockdown mediated a marked antifibrotic effect, as determined by histopathology, trichrome staining for collagen, immunohistochemical analysis of α-SMA ( Fig. 3c) and biochemical analyses of hydroxyproline content ( Fig. 3d) and acidsoluble collagen (Fig. 3e) in whole-lung homogenates.
Pharmacological approaches that specifically target fibrogenic processes are currently lacking. To determine whether pharmacologic blockade of NOX or flavoenzyme activity during the injury reparative phase after injury protects against fibrogenic tissue responses, we used the flavoenzyme inhibitor diphenyleneiodonium chloride (DPI). We administered DPI, which blocks NOX-4 activity in myofibroblasts at a relatively low half-maximal inhibitory concentration (<0.5 µM; data not shown), by daily intraperitoneal injection on days 8-21 after bleomycin lung injury. We delayed DPI administration until day 8 to minimize the effects of the drug on inflammatory responses that typically subside after the first week of bleomycin-induced lung injury in mice 21, 22 . Mice receiving DPI showed significant protection from fibrosis, as measured by acid-soluble collagen in whole lung (Fig. 3f) ; this was associated with reduced fibrosis as determined by histopathology and Masson's trichrome staining for collagen, as well as by reduced numbers of α-SMA-expressing myofibroblasts and reduced expression of NOX-4 ( Supplementary Fig. 2b) .
We also used a hapten (FITC)-driven lung fibrosis mouse model to test the role of NOX-4 in fibrogenesis 23 . In this model, we instilled Nox4 siRNA directly down the trachea of mice at the time of FITC injury (day 0), and we analyzed the tissues on day 14 or 21. This RNAi approach was effective in inhibiting NOX-4 induction at day 21 after lung injury (Fig. 4a) . The fibrotic response surrounding airways where FITC was deposited was found to be markedly attenuated in mice receiving Nox4 siRNA versus nontargeting siRNA, as determined by histopathology and trichrome staining for collagen ( Fig. 4b) ; we confirmed this by analyzing whole-lung homogenates for acidsoluble collagen by Sircol assay (Fig. 4c) and acid-insoluble collagen by hydroxyproline assay (Fig. 4d) .
In this study, we show a functional role for NOX4 in myofibroblast differentiation and activation ex vivo and in fibrogenic responses to lung injury in vivo. The profibrogenic mediator TGF-β1 specifically induces mRNA and protein expression and enzymatic activation of the NOX-4 isoform in differentiated myofibroblasts. NOX-4-dependent H 2 O 2 generation is required for myofibroblast differentiation, synthesis of ECM proteins and contractility mediated by TGF-β1. NOX-4 is expressed in the myofibroblastic foci of remodeled IPF lung tissue, supporting a role for this NOX isoform in the induction and activation of myofibroblasts in this human pulmonary disorder. Further, in two mouse models of pulmonary fibrosis, genetic or pharmacologic strategies targeting NOX-4 induction or activity protect against fibrosis. We used an RNAi strategy to suppress NOX-4 expression by administering Nox4 siRNA at the time of bleomycin or FITC injury. It is likely that the disruption of the airway-alveolar epithelial barrier immediately after bleomycin or FITC injury facilitated the transduction of siRNA to epithelial or mesenchymal precursor cells that prevented their differentiation into activated myofibroblasts, thus protecting from lung fibrosis.
These are the first studies, to our knowledge, to definitively implicate a specific NOX isoform in tissue repair functions and fibrogenesis. We speculate that NOX4 may have been selected during metazoan evolution to execute tissue repair functions crucial for the survival of more complex multicellular eukaryotes 24 . In support of this notion, NOX4 is almost exclusively expressed in chordates 25 . Furthermore, NOX-4 activation in myofibroblasts and tissue fibrogenesis may represent yet another example of antagonistic pleiotropy, whereby genes that confer a survival advantage during early reproductive life mediate potential harmful effects in later life 26 . Fibrosis is typically a complication of failed tissue regeneration and ineffective epithelial repair in diverse organ systems, often with an age-dependent increase in incidence 27 . Fibrosis in mammalian tissues is perhaps best viewed as an initial adaptive response executed by mesenchymal cells to restore tissue barrier function while secreting a provisional matrix to facilitate reepithelialization; however, persistent mesenchymal activation and failed reepithelialization results in unrestrained and progressive fibrosis. Targeting NOX-4 may prove to be an effective therapeutic strategy for an otherwise treatment-unresponsive and ultimately fatal group of human fibrotic disorders. Values represent means ± s.e.m.; n = 4-6; *P < 0.01 compared to saline, nontargeting (control) siRNA.
